Cambium Bio Limited
CMB
Rangering i aksjer
#32452
Cambium Bio Limited, a clinical-stage regenerative medicine company, focuses on... Cambium Bio Limited, a clinical-stage regenerative medicine company, focuses on developing biologics for ophthalmology and tissue repair applications. The company provides lead product candidate is Elate Ocular for the treatment of dry eye disease. The company also develops Progenza, a stem cell platform for knee osteoarthritis and other tissue repair indications; and Sygenus, for wound healing indications. Cambium Bio Limited is headquartered in Bella Vista, Australia.
Aksjekurs
$0.31613178
Sist synkronisert: 2026-10-21
Markedsverdi
$9.30M
Endring (1 dag)
-0.39%
Endring (1 år)
5,893.70%
Land
AU
Handel Cambium Bio Limited (CMB)
Kategori
Healthcare
Aksjeprishistorikk for Cambium Bio Limited (CMB)
Høyeste sluttskurs: $0.01 den 2024-05-01
Laveste sluttskurs: $0.25 den 2013-09-01
Laveste sluttskurs: $0.25 den 2013-09-01
Aksjeprishistorikk for Cambium Bio Limited fra 2013 til 2026
Årlig aksjeprisytelse
| År | Ytelse |
|---|---|
| 2024 | 119.50% |
| 2023 | -92.08% |
| 2022 | -41.49% |
| 2021 | -42.78% |
| 2020 | 56.83% |
| 2019 | -53.42% |
| 2018 | 31.72% |
| 2017 | -21.51% |
| 2016 | 74.18% |
| 2015 | -41.39% |
| 2014 | -67.54% |
| 2013 | 0.00% |
Aksjepris for lignende selskaper eller konkurrenter
| Selskap | Aksjepris | Endring 1år% | Land |
|---|---|---|---|
| $536.13 | 25.72% |
US
|
|
| $200.12 | 645.31% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $291.76 | 2.51% |
BE
|
|
| $880.01 | 8.09% |
NL
|
